Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo

The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being tested in clinical trials as a therapeutic avenue for PD, to date, the mol...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Mol Neurodegener
Päätekijät: Kluss, Jillian H., Mazza, Melissa Conti, Li, Yan, Manzoni, Claudia, Lewis, Patrick A., Cookson, Mark R., Mamais, Adamantios
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2021
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7977595/
https://ncbi.nlm.nih.gov/pubmed/33741046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13024-021-00441-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia